- Conditions
- Acute Lymphoblastic Leukemia (ALL)
- Interventions
- Sedentary time intervention
- Behavioral
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 12 Years to 21 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 284
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis
- Interventions
- MSK-ACCESS, ctDNA/VTE Risk Score:
- Diagnostic Test
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 259 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Eosinophilic Esophagitis (EoE)
- Interventions
- Esophageal String Test
- Device
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 7 Years to 17 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Mild Traumatic Brain Injury
- Interventions
- VIDAS® TBI Test [GFAP and UCH-L1 assays]
- Diagnostic Test
- Lead sponsor
- BioMérieux
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 903 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 5
- States / cities
- Orlando, Florida • Detroit, Michigan • Rochester, Minnesota + 2 more
- Conditions
- Marfan Syndrome, Marfan Related Disorders, Control Subjects
- Interventions
- Not listed
- Lead sponsor
- Shriners Hospitals for Children
- Other
- Eligibility
- 4 Years to 26 Years
- Enrollment
- 336 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2017
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Omaha, Nebraska • Portland, Oregon + 1 more
- Conditions
- Multiple Myeloma
- Interventions
- Radium-223 dichloride (Xofigo, BAY88-8223), Placebo, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 3
- States / cities
- Encinitas, California • Winston-Salem, North Carolina • Seattle, Washington
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Juvenile Myelomonocytic Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome
- Interventions
- Biospecimen Collection
- Procedure
- Lead sponsor
- PedAL BCU, LLC
- Other
- Eligibility
- Up to 22 Years
- Enrollment
- 960 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 164
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 133 more
- Conditions
- Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Interventions
- Carfilzomib, Chemosensitivity Assay, Dexamethasone, Laboratory Biomarker Analysis, Panobinostat
- Drug · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Not listed
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 29 more
- Conditions
- Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia, Refractory Hairy Cell Leukemia
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cladribine, Computed Tomography, Rituximab, Tovorafenib
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 4
- States / cities
- Bethesda, Maryland • Columbus, Ohio • Pittsburgh, Pennsylvania + 1 more
- Conditions
- Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Interventions
- Bosutinib, Dasatinib, Laboratory Biomarker Analysis, Nilotinib, Ruxolitinib, Imatinib
- Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 541
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 320 more
- Conditions
- Sickle Cell Disease
- Interventions
- Sickle Cell Collaboration for Child Development
- Behavioral
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 6 Months to 31 Months
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
- Interventions
- PI3K-beta Inhibitor GSK2636771
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Coagulation Disorder
- Interventions
- International Normal Ratio (INR)
- Diagnostic Test
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Liver Cirrhosis, Liver Cancer, HCC, Hepatocellular Carcinoma
- Interventions
- Multi-analyte Blood Test
- Diagnostic Test
- Lead sponsor
- Helio Genomics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,200 participants
- Timeline
- 2022 – 2028
- U.S. locations
- 7
- States / cities
- Escondido, California • Mission Hills, California • Gainesville, Florida + 4 more
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Interventions
- Behavioral Intervention, Survey Administration, Interview
- Behavioral · Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years to 54 Years
- Enrollment
- 374 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 2
- States / cities
- Memphis, Tennessee • Seattle, Washington
- Conditions
- Epilepsy
- Interventions
- Not listed
- Lead sponsor
- Cognizance Biomarkers, LLC
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 371 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Dysphagia, Eosinophilic Esophagitis
- Interventions
- Esophageal string test
- Device
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Coagulation Disorder
- Interventions
- Chamomile Tea, Chamomile Extract Capsule, Placebo Capsule
- Dietary Supplement
- Lead sponsor
- Stony Brook University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Stony Brook, New York
- Conditions
- Iron Deficiency Anemia
- Interventions
- stable isotope of iron, dysprosium
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 20 Years to 40 Years · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
- Interventions
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, Mirdametinib
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 8
- States / cities
- Duarte, California • Irvine, California • Sacramento, California + 5 more
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF), Iron Deficiency, Iron-deficiency Anemia (IDA)
- Interventions
- Ferric Carboxymaltose, Ferrous Sulfate
- Drug
- Lead sponsor
- Syed Hamza Mufarrih
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Bowling Green, Kentucky
- Conditions
- Multiple Myeloma
- Interventions
- Radium-223 dichloride (Xofigo, BAY88-8223), Placebo, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • Encinitas, California + 7 more
- Conditions
- Hemophilia A, Factor VIII Deficiency, Hemophilia, Hemophilia B, Factor IX Deficiency
- Interventions
- Peripheral Vein Blood draw
- Procedure
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 1 Year to 21 Years · Male only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri